1. Home
  2. EDD vs EDIT Comparison

EDD vs EDIT Comparison

Compare EDD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

HOLD

Current Price

$5.86

Market Cap

371.9M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$3.04

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDD
EDIT
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
371.9M
432.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
EDD
EDIT
Price
$5.86
$3.04
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.30
AVG Volume (30 Days)
293.4K
2.6M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
7.52%
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$4.96
$1.66
52 Week High
$6.18
$4.54

Technical Indicators

Market Signals
Indicator
EDD
EDIT
Relative Strength Index (RSI) 48.23 51.14
Support Level $5.74 $2.67
Resistance Level $6.03 $3.21
Average True Range (ATR) 0.08 0.23
MACD -0.01 0.00
Stochastic Oscillator 35.96 36.11

Price Performance

Historical Comparison
EDD
EDIT

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: